Skip to main content
ScholarsBetaWeill Cornell Medicine

Highlights

  1. 1
    Future oncology (London, England) · 2020
    ACAnna C Pavlick
    PMID: 33084375DOIFirst author29 citations

Publications

174 publications

Funding

1 grantView NIH portfolio on RePORTER ↗
Completed grants (1)
  • MPI
    NSABP P-2: STUDY OF TAMOXIFEN AND RALOXIFENE( STAR) TO PREVENT BREAST CANCER
    NCRR · 2004–2006 · via NIH RePORTER
    M01RR000096-44

Clinical research

12 studies

Active

4 studies
  • PI
    A Single Arm Study With Safety Run-in of Peptide Receptor Radionuclide Therapy (PRRT) in Combination With Immunotherapy for Patients With Merkel Cell Cancer (HCRN MCC20-443; iPRRT Study)
    PHASE2 · Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2025)
    Merkel Cell Carcinoma
    NCT05583708
  • PI
    A Phase 1/2, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of GIM-531 as a Single Agent and in Combination With Anti-PD-1 in Advanced Solid Tumors
    PHASE1; PHASE2 · Georgiamune Inc · OPEN TO ACCRUAL (as of 2025)
    Melanoma Stage IV; Solid Tumor
    NCT06425926
  • PI
    Tumor Glycolytic Index: A Potential Predictive Biomarker for Immunotherapy Response in Metastatic Melanoma
    Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2025)
  • PI
    Response to Immunotherapy Following Vaccine Treatment for Advanced Melanoma
    Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2024)
Completed & closed trials (8)
  • PI
    A Phase 1/2, Open-Label, Multi-Center, Dose Escalation and Expansion Study of KB707 in Subjects With Locally Advanced or Metastatic Solid Tumor Malignancies
    PHASE1; PHASE2 · Krystal Biotech, Inc. · IRB STUDY CLOSURE (as of 2026)
    Cancer; Melanoma Stage III; Melanoma Stage IV; Cutaneous Melanoma
    NCT05970497
  • PI
    A Phase 1/2, Open Label, Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors
    PHASE1; PHASE2 · Tallac Therapeutics, Inc. · IRB STUDY CLOSURE (as of 2026)
    Advanced or Metastatic Solid Tumors
    NCT05399654
  • PI
    An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors [IGNYTE]
    PHASE2 · Replimune Inc. · CLOSED TO ACCRUAL (as of 2025)
    Non-Small Cell Lung Cancer (NSCLC); Microsatellite Instability-High (MSI-H); Non-melanoma Skin Cancer (NMSC); Cutaneous Melanoma
    NCT03767348
  • PI
    A Phase 1/2a, Open-Label, Multicenter, Nonrandomized, Safety and Anti-tumor Activity Study of IMM-1-104, a Novel Oral Dual MEK1/2 Inhibitor in Participants With Advanced or Metastatic Solid Tumors
    PHASE1; PHASE2 · Immuneering Corporation · CLOSED TO ACCRUAL (as of 2025)
    Advanced Solid Tumor; Pancreatic Adenocarcinoma; Malignant Melanoma (Cutaneous); Non-small Cell Lung Cancer (NSCLC)
    NCT05585320
  • PI
    A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab With Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants With High-risk Stage II-IV Melanoma (KEYVIBE-010)
    PHASE3 · Merck & Co., Inc. · IRB STUDY CLOSURE (as of 2025)
    Melanoma
    NCT05665595
  • PI
    A Phase 1 Open-label, Multicenter, Dose-ranging Study to Investigate Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types
    PHASE1 · Molecular Templates, Inc. · IRB STUDY CLOSURE (as of 2024)
    Non Small Cell Lung Cancer; Hepatocellular Carcinoma; Melanoma; Renal Cell Carcinoma; Microsatellite Instability High; Mismatch Repair Deficiency; Mesothelioma; Esophageal Squamous Cell Carcinoma; Squamous Cell Carcinoma of Head and Neck; Urothelial Carcinoma; Cervical Cancer
    NCT06034860
  • PI
    A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects With Advanced Malignancies
    PHASE1 · Seagen Inc. · IRB STUDY CLOSURE (as of 2023)
    Non-small Cell Lung Cancer; Gastric Carcinoma; Gastroesophageal Junction Carcinoma; Classical Hodgkin Lymphoma; Diffuse Large B-cell Lymphoma; Peripheral T-cell Lymphoma; Cutaneous Melanoma; Head and Neck Squamous Cell Carcinoma; Bladder Cancer; Ovarian Cancer; Triple Negative Breast Cancer; Cervical Cancer
    NCT04254107
  • PI
    A Randomized, Controlled, Open-Label, Phase 2 Study of Cemiplimab as a Single Agent and in Combination With RP1 in Patients With Advanced Cutaneous Squamous Cell Carcinoma
    PHASE2 · Replimune Inc. · IRB STUDY CLOSURE (as of 2023)
    Cutaneous Squamous Cell Carcinoma; Advanced Cutaneous Squamous Cell Carcinoma; Metastatic Cutaneous Squamous Cell Carcinoma
    NCT04050436